Angiotensin-converting enzyme 2 (ACE2) is an important factor in coronavirus disease (COVID-19) interactions. Losartan (LOS) belongs to the angiotensin receptor blocker (ARB) family. Additionally, the protective role of ACE2 restored by LOS has been suggested and clinically examined in the treatment of COVID-19 patients. Furthermore, clinical trials with LOS have been conducted. However, the mechanism through which LOS enhances ACE2 expression remains unclear. In addition, the response of ACE2 to LOS differs among patients. Our LOS-treated patient data revealed a correlated mechanism of ACE2 with components of the renin-angiotensinogen system. We observed a significant positive regulation of MAS1 and ACE2 expression. In the context of LOS treatment of COVID-19, ACE2 expression could depend on LOS regulated MAS1. Thus, MAS1 expression could predict the COVID-19 treatment response of LOS.
【저자키워드】 Medical research, Health care, 【초록키워드】 COVID-19, Treatment, coronavirus disease, ACE2, clinical trial, ARB, ACE2 expression, expression, patients, predict, interactions, mechanism, COVID-19 patients, angiotensin receptor blocker, patient data, LOS, Treatment response, Regulation, enzyme, protective role, component, positive, ENhance, MAS1, examined, addition, clinically, conducted, suggested, correlated, regulated, restored, 【제목키워드】 COVID-19, Treatment, ACE2, RAS, component,